Valuing Human Trials
Executive SummaryWhat kind of premiums, if any, do pharmaceutical licensees pay to biotech licensors who have managed to bring the licensed compound into human trials, as opposed to preclinical candidates?
You may also be interested in...
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.